Foto FAU

The search for a vaccine against COVID-19 will take months, perhaps even years. Until that time, a drug that can combat the worst symptoms of the virus would be worth its weight in gold. The anti-malarial drug Hydroxychloroquine, pushed by Donald Trump, is unlikely to deliver that. But the German Friedrich-Alexander University Erlangen-Nürnberg (FAU) might have found something that does work.

Get full access to our archive by becoming a member of Innovation Origins. Sign up here as a supporter of independent journalism!

Become a member!

On Innovation Origins you can read the latest news about the world of innovation every day. We want to keep it that way, but we can't do it alone! Are you enjoying our articles and would you like to support independent journalism? Become a member and read our stories guaranteed ad-free.

About the author

Author profile picture Maurits Kuypers graduated as a macroeconomist from the University of Amsterdam, specialising in international work. He has been active as a journalist since 1997, first for 10 years on the editorial staff of Het Financieele Dagblad in Amsterdam, then as a freelance correspondent in Berlin and Central Europe. When it comes to technological innovations, he always has an eye for the financial feasibility of a project.